PAVmed Inc.

PAVmed reported second-quarter GAAP net loss of $5.5 million, or $0.87 per share, versus a prior-year loss of $12.3 million; on a non-GAAP basis, loss was $1.7 million, or $0.27 per share. GAAP net loss before NCI and preferred dividends was $6.6 million versus $12.3 million a year ago, helped by a smaller non-cash fair-value charge of about $3.1 million versus $10.8 million last year. Second-quarter non-GAAP operating expenses were $6.1 million, up about $200,000 sequentially and about $400,000 above the last four-quarter average, while non-GAAP R&D rose about $650,000 sequentially and $1.3 million year over year. Cash at June 30 was $3.8 million. Looking ahead, management said OpEx increases are likely to be tied mostly to Veris R&D as the implantable device moves toward FDA submission and clearance. They also noted expected future liquidity from $30 million of warrants callable after a positive EsoGuard LCD and $2.5 million from Veris warrants callable upon FDA clearance of the Veris implantable device.

Dr. Aklog’s tone was constructive and confident, centered on a diversified portfolio making tangible progress. He framed Lucid, Veris, PortIO, and Octeris as multiple “shots on goal” and said the company remains firmly committed to the diversified model. On PortIO, he stressed that a 510(k) pathway is not certain but could materially shorten development time and lower capital requirements; on Octeris, he said the project is still several years away but technical progress is encouraging.

Dennis McGrath focused on the balance sheet and the quarter’s non-cash items. He reiterated the February financing actions, including the $30 million Series D preferred offering and the $15 million senior secured note with February 2029 maturity, and noted that the Series D was mandatorily converted and eliminated. He said cash was $3.8 million at June 30, excluding potential future warrant proceeds, and that PAVmed’s equity-method investment balance was $33 million based on 31.3 million Lucid shares marked at $1.07. He also highlighted that the improved GAAP loss was largely driven by a lower non-cash fair-value charge, while higher R&D was mainly due to Veris implantable device work.

Analysts pressed for more detail on Veris commercialization, but management declined to give hard patient counts. Instead, Aklog said the OSU/The James program still targets 1,000 registry patients over a year, enrollment has accelerated over the last couple of months, and two-thirds of departments are now onboarding. Questions on PortIO focused on timeline and regulatory route; management said the pre-submission meeting request will be submitted in the fourth quarter, the meeting itself may slip into early 2027, and a 510(k) route may be possible because of the published first-in-human data. On Octeris, management said validation will largely prove ergonomics and usability for the smaller, more user-friendly probe, and that the broader project remains several years from commercialization.